

EU DECLARATION OF CONFORMITY (DoC)

Manufacturer:	Becton, Dickinson and Company BD Biosciences 155 North McCarthy Boulevard Milpitas, California 95035 USA
Manufacturer SRN:	US-MF-000017797
Authorised Representative:	Becton Dickinson Ireland Ltd. Donore Road, Drogheda Co. Louth, A92 YW26 Ireland
Authorised Representative SRN:	IE-AR-000007610
Product:	<p>CD56 (MY31) BD® CD56(MY31) PE REF 345810</p> <p>CD56 (NCAM16.2) BD® CD56(NCAM16.2) FITC REF 345811 BD® CD56(NCAM16.2) PE REF 345812 BD® CD56(NCAM16.2) PE-Cy7 REF 335826 BD® CD56(NCAM16.2) APC REF 341027 BD® CD56 (NCAM16.2) APC-R700 REF 664456</p>
Basic UDI-DI:	038290KSLVXUHTPM
Risk Class and Rule :	Class C, Annex VIII, Rule 3(g) & Rule 3(h)
Intended Purpose:	<p>CD56 (MY31) CD56 (MY31) is intended for in vitro diagnostic use in the identification of cells expressing the CD56 antigen in peripheral blood, using a BD FACSLyric™ flow cytometer. <u>Clinical Applications</u> Expression of the CD56 antigen in the characterization of subjects having, or suspected of having, hematological neoplasia.</p> <p>CD56 (MY31) is a qualitative reagent intended for laboratory professional use only.</p> <p>CD56 (NCAM16.2) CD56 (NCAM16.2) is intended for in vitro diagnostic use in the identification of cells expressing the CD56 antigen in peripheral blood, using a BD FACSLyric™ flow cytometer. <u>Clinical Applications</u> Expression of the CD56 antigen in the characterization of subjects having, or suspected of having, hematological neoplasia.</p>

	CD56 (NCAM16.2) is a qualitative reagent intended for laboratory professional use only.
Notified Body:	BSI Group The Netherlands B.V. Say Building, John M. Keynesplein 9, 1066 EP Amsterdam, Netherlands Notified Body Number: 2797
We, as the manufacturer of the device(s) take sole responsibility for and hereby declare that the above-mentioned product(s) meet(s) the provisions of the following Directives/ Regulation(s): <ul style="list-style-type: none"> Regulation (EU) 2017/746 on In vitro Diagnostic Medical Devices. 	


Conformity Assessment Route:

<input type="checkbox"/> ANNEX IX Technical File Examination	EC CERTIFICATE No.: EC Certificate Expiration Date:
<input checked="" type="checkbox"/> ANNEX IX Full Quality System	EC CERTIFICATE No.: 728780 R000 EC Certificate Expiration Date: 2025-December-16
<input type="checkbox"/> ANNEX X Type Examination	EC CERTIFICATE No.: EC Certificate Expiration Date:
<input type="checkbox"/> ANNEX XI Production Quality System	EC CERTIFICATE No.: EC Certificate Expiration Date:
<input type="checkbox"/> ANNEX I & II+III	N/A

Common Specifications (CS):

Common Specifications have not been issued for this product.



Authorised Signatory:	
Name & Title:	Mirna Dipano, Vice President, Regulatory Affairs
On behalf of:	Becton, Dickinson and Company BD Biosciences 155 North McCarthy Boulevard Milpitas, California 95035 USA
Place of Issue:	Milpitas, California USA
Date of Issue:	Please refer to Signature section.
Signature:	<div><div>DocuSigned by:</div><div><i>Mirna Dipano</i></div><div> Signer Name: Mirna Dipano Signing Reason: I approve this document Signing Time: 05-Jul-2023 4:12:07 PM PDT 6166B70768DA44C1A0CA7A9871E2F40A</div></div>

DECLARATION OF CONFORMITY Revision History:

Version:	Detailed Change Description:
A	Initial creation of document
B	Updated SRN of EU Authorized Representative
C	Update to accommodate with Corporate Template CBI-058 FRM24. Added SRN for legal manufacturer.
D	Updated to Corporate Template CBI-058 FRM24 Revision 04. Updated Risk Class & Rule section by replacing “Class C, Annex VIII Rule 3” with “Class C, Annex VIII, Rule 3(g) & Rule 3(h)” to support global registration.
E	Updated Manufacturer and Authorised Signatory to include Milpitas address. Update to Name & Title to current PRRC. Updated product description names to include trademarks